SCHEMBL2332878

SCHEMBL2332878

COC(=O)c1cccn1CC(=O)c1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 1/20 0.50
PLOD2 O00469 2/20 0.44
PLOD3 O60568 2/20 0.44
PLOD1 Q02809 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
HIF1A Q16665 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
ALOX12 P18054 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM1A O60341 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2333161 0.85 ALDH1A1 (0.56) ALDH1A1KDM4EPLOD2PLOD3PLOD1
SCHEMBL2334312 0.84 ALDH1A1 (0.54) ALDH1A1KDM4ELMNAMEN1MAPT
SCHEMBL2330853 0.83 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDLMNAMAPT
SCHEMBL2333971 0.83 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL2330773 0.83 KDM4E (0.70) ALDH1A1KDM4ELMNAMEN1MAPT
SCHEMBL15287319 0.83 ALDH1A1 (0.50) ALDH1A1KDM4ELMNAMAPTMAPK1
SCHEMBL2334137 0.82 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDLMNAMEN1
SCHEMBL24435270 0.81 FLT1 (0.42) ALDH1A1KDM4EUSP2MAPK10
SCHEMBL25395065 0.80 USP2 (0.51) ALDH1A1KDM4ECYP1A2CYP3A4CYP2C9
SCHEMBL24434999 0.78 HDAC3 (0.43) ALDH1A1KDM4EUSP2MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2534155-B1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENT MANAGEMENT PTY LTD (AU) 2018-04-11 EP disclosed
US-9540387-B2 Substituted imidazo[1,2-d]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2017-01-10 US disclosed
CN-102844318-B Be used for the treatment of the compound of respiratory syncytial virus infection BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2016-04-13 CN disclosed
US-20160046642-A1 Compounds for Treating Respiratory Syncytial Virus Infections BIOTA SCIENT MANAGEMENT (AU) 2016-02-18 US disclosed
US-9163029-B2 Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2015-10-20 US disclosed
US-20140051697-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2014-02-20 US disclosed
US-8604034-B2 Substituted imidazo[1,2-α]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus (RSV) infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2013-12-10 US disclosed
CN-102844318-A Compounds for treating respiratory syncytial virus infections BIOTA SCIENT MAN 2012-12-26 CN disclosed
EP-2534155-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS Biota Scientific Management Pty Ltd (AU) 2012-12-19 EP disclosed
US-20110207728-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2011-08-25 US disclosed
WO-2011094823-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207728-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS FURIN, SQOR, SUCNR1 ALDH1A1 609/4885KDM4E 4061/4885PLOD2 4512/4885
US-20160046642-A1 Compounds for Treating Respiratory Syncytial Virus Infections FURIN, SQOR, SUCNR1 ALDH1A1 609/4885KDM4E 4061/4885PLOD2 4512/4885
US-20140051697-A1 COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS FURIN, SQOR, SUCNR1 ALDH1A1 609/4885KDM4E 4061/4885PLOD2 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.